Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Dexpramipexole Administered Orally for 52 Weeks in Participants With Severe Eosinophilic Asthma

NCT05763121 is registered in ClinicalTrials.gov with Areteia Therapeutics as lead sponsor.

NCT NCT05763121
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05763121 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Dexpramipexole Administered Orally for 52 Weeks in Participants With Severe Eosinophilic Asthma
Lead sponsor
Areteia Therapeutics
Phase
Phase 3
Overall status
Terminated
Start date
January 30, 2023
Completion date
December 8, 2025
Enrollment
1,061 (actual)
Sites
401

Conditions

As the registry lists them; a condition with its own page is linked.

asthma, asthma; eosinophilic, eosinophilic asthma